Skip to main content
. 2014 Oct 21;11(1):203–211. doi: 10.3892/mmr.2014.2718

Figure 4.

Figure 4

Knockdown of c-FLIP mimics the effect of rocaglamide in sensitizing HepG2 cells to TRAIL. The HepG2 cells were transiently transfected with either siRNA specific for c-FLIP or a control for 48 h and were then treated with TRAIL (100 ng/ml) for 12 h. (A) Western blot analysis indicating the expression levels of c-FLIP in the c-FLIP-silenced and control cells. (B) Cells were washed with PBS and fixed with 4% paraformaldehyde followed by staining using crystal violet. (C) Representative images of c-FLIP-silenced HepG2 and control cells. (D and E) Cell apoptosis was determined using flow cytometry with annexin/PI double staining in the c-FLIP-knockdown HepG2 and control cells (magnification, ×400). Data are expressed as the mean ± standard deviation. *P<0.01, siRNA-FLIP+TRAIL group vs siRNA-control+TRAIL group. Results are representative of three independent experiments. TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; DMSO, dimethyl sulfoxide; c-FLIP, cellular FLICE-like inhibitory protein; PI, propidium iodide.